

# Proposed Rules

This section of the FEDERAL REGISTER contains notices to the public of the proposed issuance of rules and regulations. The purpose of these notices is to give interested persons an opportunity to participate in the rulemaking prior to the adoption of the final rules.

## DEPARTMENT OF JUSTICE

Bureau of Narcotics and Dangerous Drugs

[ 21 CFR Part 308 ]

### 4-BROMO-2,5-DIMETHOXYAMPHETAMINE

#### Proposed Placement in Schedule I

Based upon the investigations of the Bureau of Narcotics and Dangerous Drugs and upon the scientific and medical evaluation and recommendation of the Secretary of Health, Education, and Welfare, received pursuant to section 201 (b) of the Comprehensive Drug Abuse Prevention and Control Act of 1970 (21 U.S.C. 811(b)), the Director of the Bureau of Narcotics and Dangerous Drugs finds that 4-bromo-2,5-dimethoxyamphetamine (and its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation):

- (1) Has a high potential for abuse;
- (2) Has no currently accepted medical use in treatment in the United States; and
- (3) Lacks accepted safety for use under medical supervision.

Therefore, under the authority vested in the Attorney General by section 201 (a) of the Comprehensive Drug Abuse Prevention and Control Act of 1970 (21 U.S.C. 811(a)), and delegated to the Director of the Bureau of Narcotics and Dangerous Drugs by § 0.100 of Title 28 of the Code of Federal Regulations, the Director proposes that § 308.11(d) of Title 21 of the Code of Federal Regulations be amended by adding a new paragraph (18) to read:

#### § 308.11 Schedule I.

(d) \* \* \*

- (18) 4-bromo-2,5-dimethoxyamphetamine ----- 7391  
Some trade or other names:  
4-bromo-2,5-dimethoxy- $\alpha$ -methylphenethylamine:  
4-bromo-2,5-DMA.

All other interested persons are invited to submit their comments or objections in writing regarding this proposal. These comments or objections should state with particularity the issues concerning which the person desires to be heard. A person may comment on or object to the application of this proposal to any one or more of the nine derivatives named without filing comments on the remaining derivatives. Comments and objections should be submitted in quintuplicate to the Hearing Clerk, Office of Chief Counsel,

Bureau of Narcotics and Dangerous Drugs, Department of Justice, Room 611, 1405 I Street, NW., Washington, D.C. 20537, and must be received no later than August 1, 1973.

In the event that an interested party submits objections to this proposal which present reasonable grounds for this rule not to be finalized and requests a hearing in accordance with 21 CFR 308.45, the party will be notified by registered mail that a hearing on these objections will be held at the time and place set forth in the letter. A notice of hearing will simultaneously be published in the FEDERAL REGISTER. If objections submitted do not present such reasonable grounds, the party will so be advised by registered mail.

If no objections presenting reasonable grounds for a hearing on the proposal are received within the time limitations, and all interested parties waive or are deemed to waive their opportunity for the hearing or to participate in the hearing, the Director may cancel the hearing and, after giving consideration to written comments, issue his final order pursuant to 21 CFR 308.48 without a hearing.

Dated: June 27, 1973.

JOHN E. INGERSOLL,  
Director, Bureau of  
Narcotics and Dangerous Drugs.

[FR Doc.73-13447 Filed 6-29-73;8:45 am]

[ 21 CFR Part 308 ]

### 4-METHOXYAMPHETAMINE

#### Proposed Placement in Schedule I

Based upon the investigations of the Bureau of Narcotics and Dangerous Drugs and upon the scientific and medical evaluation and recommendation of the Secretary of Health, Education, and Welfare, received pursuant to section 201 (b) of the Comprehensive Drug Abuse Prevention and Control Act of 1970 (21 U.S.C. 811(b)), the Director of the Bureau of Narcotics and Dangerous Drugs finds that 4-Methoxyamphetamine (and its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation):

- (1) Has a high potential for abuse;
- (2) Has no currently accepted medical use in treatment in the United States; and
- (3) Lacks accepted safety for use under medical supervision.

Therefore, under the authority vested in the Attorney General by section 201

(a) of the Comprehensive Drug Abuse Prevention and Control Act of 1970 (21 U.S.C. 811(a)), and delegated to the Director of the Bureau of Narcotics and Dangerous Drugs by § 0.100 of Title 28 of the Code of Federal Regulations, the Director proposes that § 308.11(d) of Title 21 of the Code of Federal Regulations be amended by adding a new paragraph (18) to read

#### § 308.11 Schedule I.

(d) \* \* \*

- (18) 4-methoxyamphetamine ----- 7411  
Some trade or other names:  
4-methoxy- $\alpha$ -methylphenethylamine;  
paramethoxyamphetamine; PMA.

All other interested persons are invited to submit their comments or objections in writing regarding this proposal. These comments or objections should state with particularity the issues concerning which the person desires to be heard. A person may comment on or object to the application of this proposal to any one or more of the nine derivatives named without filing comments on the remaining derivatives. Comments and objections should be submitted in quintuplicate to the Hearing Clerk, Office of Chief Counsel, Bureau of Narcotics and Dangerous Drugs, Department of Justice, Room 611, 1405 I Street, NW., Washington, D.C. 20537, and must be received no later than August 1, 1973.

In the event that an interested party submits objections to this proposal which present reasonable grounds for this rule not to be finalized and requests a hearing in accordance with 21 CFR 308.45, the party will be notified by registered mail that a hearing on these objections will be held at the time and place set forth in the letter. A notice of hearing will simultaneously be published in the FEDERAL REGISTER. If objections submitted do not present such reasonable grounds, the party will so be advised by registered mail.

If no objections presenting reasonable grounds for a hearing on the proposal are received within the time limitations, and all interested parties waive or are deemed to waive their opportunity for the hearing or to participate in the hearing, the Director may cancel the hearing and, after giving consideration to written comments, issue his final order pursuant to 21 CFR 308.48 without a hearing.

Dated: June 27, 1973.

JOHN E. INGERSOLL,  
Director, Bureau of  
Narcotics and Dangerous Drugs.

[FR Doc.73-13448 Filed 6-29-73;8:45 am]